AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01110018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK573719 (INHALATION POWDER)
Description: 500μg inhalation powder delivered via Novel Dry Powder Inhaler. GSK573719 1000μg per dose (2x 500μg strips in device).
Study NCT03612921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral Amantadine sulfate
Description: oral amantadine
Study NCT00570492 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: Placebo nasal spray
Study NCT00880295 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open carpal tunnel release
Description: open surgery, which is standard of care for carpal tunnel release
Study NCT03580681 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant-based diet
Description: Weekly instructions will be given to the participants in the intervention group about following vegan diet.
Study NCT03580681 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Supplement
Description: Unrestricted diet with clinically insignificant amount of omega- 3 oils and vitamin E
Study NCT04306263 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enriched infant formula
Description: Infant formula enriched with dairy ingredients: osteopontin, prebiotics and probiotics
Study NCT04306263 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard formula
Description: Infants receiving a standard infant formula.
Study NCT04306263 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Breastfeeding arm
Description: Infants exclusively or predominantly breastfed (>75%).
Study NCT01568294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: 2 mg or 4mg oral pomalidomide once per day on Days 1-21 of a 28-day cycle
Study NCT00595491 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bronchoscopy, Segmental Allergen Challenge, and Broncheoalveolar Lavage
Description: Bronchoalveolar lavage is performed in the lingula without instillation of diluent or allergen. A 2ml aliquot of diluent is instilled into the right upper lobe. The procedure is repeated in the right middle lobe with instillation of 2ml of Cat or Mite allergen. A test dose of allergen is administered first. This will consist of 2ml allergen at 1/10th the threshold concentration for Cat or DF Mite Allergen or at 1/30th the threshold concentration for DP Mite Allergen. If on visual inspection through the bronchoscope there is no evidence of reaction to the test dose, a 2nd allergen challenge is done in the right middle lobe using 2ml of full-dose allergen. After a 1,6, or 24hr recovery period, a single 2nd bronchoscopy is performed after delivery of allergen extract and diluent and 1 Tbsp of blood is obtained. Bronchoalveolar lavage will be obtained from the lobes in which the diluent and allergen were instilled. OFDI and endobronchial brushing of the airways will also be performed.
Study NCT01994044 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical fusion
Study NCT03255577 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node Biopsy (SLNB)
Description: Sentinel Lymph Node Biopsy Patients with locally advanced breast cancer will undergo SLNB with dual tracer mapping followed by completion axillary lymph node dissection.
Study NCT04158583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7296682
Description: RO7296682 will be administered by the schedules specified in the respective arms.
Study NCT02742545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MayoExpertAdvisor
Description: Access to MayoExpertAdvisor (MEA) in the electronic medical record (EMR). MEA will provide patient-specific knowledge and treatment suggestions for patients with hyperlipidemia, atrial fibrillation, and/or heart failure via a clickable tab in the Mayo Clinic EMR.
Study NCT03753555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin Calcium
Description: 20mg Qd for 12 months
Study NCT03753555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin Calcium
Description: 40-80mg Qd for 6 months
Study NCT03753555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probucol
Description: 0.5g Bid for 6 months
Study NCT03753555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitor
Description: Evolocumab 140mg subcutaneously injected, twice each month
Study NCT02457676 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alert Program for Self-Regulation
Description: Children attend 12 1.5 hour weekly sessions. Alert uses the analogy of a car engine to help children identify their own self-regulatory behavior. Children learn strategies to regulate their own engine speed in different situations.
Study NCT02430064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low PAMP diet
Study NCT02593331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFKB8488A
Description: Participants will receive either a single escalated dose of BFKB8488A administered SC or a single dose of BFKB8488A administered IV on Day 1.
Study NCT02829749 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control
Description: traditional mitral valve repair performed under cardiac arrest
Study NCT00254995 — intervention group
Intervention type: BIOLOGICAL
Intervention: None administered in this study
Description: N/A in this study
Study NCT02547662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT02547662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO
Study NCT02547662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02547662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given PO
Study NCT04182035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient-tailored therapy
Description: The subjects in the PTT group will receive the individual tailored treatment program combining best evidence active and passive treatment strategies (manual therapy, individual exercises) in combination with education tailored to the individual situation of the patient and selected home exercises. 9 individual therapy sessions will be performed, in combination with 9 additional home exercise sessions.. NRS and NDI-scores will be monitored before every treatment. The therapist will register when the cut-off score of 30% NDI reduction is present in order to determine the evolution in pain/disability reduction. The importance of self-efficacy will be emphasized and tailored home-exercises will be monitored and adjusted every week.
Study NCT04182035 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-patient tailored therapy: generalized exercise program
Description: The NPTT will receive an individual (hands-off) treatment, which includes an active neck exercise program, non-tailored education and non-tailored home exercises, according to a previously published program with good results.53 The sessions will be performed once a week under supervision (9 therapy sessions, standard exercise program) and once a week by the patient at home (9 home exercise sessions, standard exercise program).
Study NCT04182035 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Education considering neck pain information
Study NCT04182035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Education considering neck pain information
Study NCT01911507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Description: Given PO
Study NCT01911507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO
Study NCT02789176 — intervention group
Intervention type: OTHER
Intervention: Surveys
Description: Regarding development, epilepsy, and family impact
Study NCT02593331 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single dose of placebo on Day 1.
Study NCT02789176 — intervention group
Intervention type: OTHER
Intervention: EEG
Study NCT00733720 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suboxone
Description: 4/1mg, 8/2mg 16/4mg
Study NCT01024543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Description: Angiotensin II
Study NCT01024543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Phenylephrine
Study NCT01024543 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Study NCT03395366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multifaceted Educational / Cognitive Behavioral Intervention
Description: The intervention includes 8 to 12 one-on-one sessions over a 12-week period, run by a licensed social worker (LSW) with experience delivering therapy. Curriculum will introduce education relevant for self-management and consists of prepared slides, handouts \& worksheets. The education was designed based on slides developed and published online by the national kidney foundation and the national kidney disease education program. The curriculum was designed to be understandable by all potential subjects, including those with low literacy levels. Sessions will incorporate behavior-based activities designed to deliver education about and improve upon medication adherence, diet, exercise, and coping. These activities, based around CB strategies such as cognitive restructuring and behavior shaping, will include review of self-management logs, goal setting, creation of treatment plan, problem-solving techniques, reinforcing techniques, and coping with ESRD.
Study NCT01654965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01654965 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC
Study NCT01654965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01654965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: Given PO
Study NCT01654965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV
Study NCT02693574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Study NCT02693574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Study NCT03571087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL140 5/10
Description: 1) Treatment(W0\~W8), Extension(W9\~W20): 6Tab./q.d. HL140 5/10(Rosuvastatin5mg/Ezetimibe10mg) : ●♤♡□△◇~●: HL140 5/10mg, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab.5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo
Study NCT03199989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CapeOX（Capecitabine+Oxaliplatin）
Description: Patients enrolled in the chemotherapy group would receive postoperative chemotherapy CapeOX（Capecitabine+Oxaliplatin）for 6 months
Study NCT03199989 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: Patients enrolled in the observation group would not receive any chemotherapy drugs just for observation
Study NCT02181543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: 1μg/Kg, IV (in the vein) intraoperative. Number of Cycles: single dose.
Study NCT03135873 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mastiha
Description: Mastiha is a natural product of Greece and has a license of manufactures Foods for Particular Nutritional Uses and of National Organization of Medicines (EOF).
Study NCT03135873 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is designed to have identical characteristics with verum.
Study NCT01355380 — intervention group
Intervention type: DRUG
Intervention: Inhaled iloprost (Ventavis, BAYQ6256)
Description: Patients treated with inhaled iloprost (Ventavis) 2.5 or 5 micrograms 6-9 times daily
Study NCT03093480 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rFVIIIFc
Description: rFVIIIFc 200 IU/kg/day in ITI Period, 50 or 100 IU/kg (adjusted according to Investigator judgement) in tapering Period, and prophylactic regimen in Follow-Up period as powder for injection administered intravenously.
Study NCT03701971 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: evaluation of the intensity of pruritus
Description: evaluation of the intensity of pruritus with various questionnaires
Study NCT03701971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: evaluation of the intensity of pruritus
Description: evaluation of the intensity of pruritus with various questionnaires
Study NCT03057769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Papillary epinephrine spraying
Description: All patients in this group receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
Study NCT03057769 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Papillary saline spraying
Description: All patients in this group receive 20 ml of saline sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
Study NCT03057769 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Indomethacin
Description: All patients without contraindications should be administrated with rectal indomethacin within 30 min before ERCP.
Study NCT03057769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: All patients without contraindications should be administrated with rectal indomethacin within 30 min before ERCP.
Study NCT04249934 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeinated Coffee
Description: A single 8 ounce cup of regular starbucks coffee will be given to the participant in the am post operative day two. Participants will have 15 minutes to consume the coffee. Additionally, medical record data will be collected up to 30 days after surgery.
Study NCT04249934 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DecaffeinatedCoffee
Description: A single 8 ounce cup of decaffeinated starbucks coffee will be given to the participant in the am post operative day two. Participants will have 15 minutes to consume the coffee. Additionally, medical record data will be collected up to 30 days after surgery.
Study NCT02738931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg tablet
Description: A white, film-coated, round tablet debossed with SV 572 on one side and 50 on the other side. Single dose of one tablet will be administered with 240 mL of water.
Study NCT02738931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine 300 mg tablet
Description: Gray, diamond-shaped tablet, engraved GX EJ7 on one side and plain on the other side. Single dose of one tablet will be administered with 240 mL of water.
Study NCT02738931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)
Description: Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.
Study NCT02738931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)
Description: Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.
Study NCT03321773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triple therapy plus bismuth therapy
Description: pantoprazole 40mg twice daily for 14 days, amoxicillin 1g twice daily for 14 days, clarithromycin 500mg twice daily for 14 days, bismuth subcitrate 240mg twice daily for 14 days.
Study NCT03321773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: reverse hybrid therapy
Description: (pantoprazole 40mg twice daily for 7 days, amoxicillin 1 g twice dailyfor 7 days, clarithromycin 500 mg twice daily for 7 days, and metronidazole 500 mg twice daily for 7 days) followed by (pantoprazole 40mg twice daily for 7 days and amoxicillin 1 g twice daily for 7 days)
Study NCT03380091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral medication daily
Study NCT03380091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Oral medication daily
Study NCT03571087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL140 10/10
Description: 1) Treatment(W0\~W8), Extension(W9\~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg) : ○♠♡□△◇~○: HL140 5/10mg placebo, ♠: HL140 10/10mg, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo
Study NCT03571087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL140 20/10
Description: 1) Treatment(W0\~W8), Extension(W9\~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg) : ○♤♥□△◇~○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♥: HL140 20/10mg, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo
Study NCT03571087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5mg → HL140 5/10
Description: 1. Treatment(W0\~W8): 6Tab./q.d. Rosuvastatin 5mg : ○♤♡■△◇~   ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo,♡: HL140 20/10mg placebo, ■: Crestor Tab. 5mg, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo~2. Extension period(W9\~W20): 6Tab./q.d. HL1405/10(Rosuvastatin5mg/Ezetimibe10mg) : ●♤♡□△◇~   * HL140 5/10mg, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo
Study NCT03571087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10mg → HL140 10/10
Description: 1. Treatment(W0\~W8): 6Tab./q.d. Rosuvastatin 10mg : ○♤♡□▲◇~   ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, ▲: Crestor Tab. 10mg, ◇: Crestor Tab. 20mg placebo~2. Extension period(W9\~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg) : ○♠♡□△◇~   * HL140 5/10mg placebo, ♠: HL140 10/10mg, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo
Study NCT03571087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg → HL140 20/10
Description: 1. Treatment(W0\~W8): 6Tab./q.d.Rosuvastatin 20mg : ○♤♡□△◆~   ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◆: Crestor Tab. 20mg~2. Extension period(W9\~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg) : ○♤♥□△◇ ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♥: HL140 20/10mg, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo
Study NCT01963390 — intervention group
Intervention type: DRUG
Intervention: Testosterone Therapy
Description: In this observational study we will be enrolling testosterone deficient men who intend to undergo testosterone therapy.
Study NCT02170584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 953 ZW IV
Study NCT02170584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS tablet
Study NCT02170584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBR 1048 MS oral solution
Study NCT03612921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: i.v Amantadine Sulfate
Description: intra venous amantadine
Study NCT03612921 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablet
Description: placebo tablet
Study NCT00749905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low fiber diet
Description: Low fiber diet for 5 days prior to colon capsule
Study NCT00749905 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: regular diet
Description: Regular diet until 1 day before colon capsule
Study NCT02816983 — intervention group
Intervention type: RADIATION
Intervention: SBRT
Study NCT03236090 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vivomixx
Description: Vivomixx®sachets containing 450 x 109 bacteria, 2 every 12 hours (n=25), or placebo (n=25)
Study NCT03321682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Training
Description: Exercises performed in circuit, using weights, elastic bands, suspension tapes, cones and on unstable surfaces.
Study NCT02170584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BIBR 953 ZW IV Placebo
Study NCT02759068 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sounds and odors
Description: presentation of sounds and odors
Study NCT02759068 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sounds and odors
Description: presentation of sounds and odors
Study NCT03321682 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength Training
Description: Exercises carried out using weights and involving the main muscle groups.
Study NCT03164499 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual counselling on lifestyles
Description: Individual standardized counselling on healthy diet, daily physical activity, stress management, smoking cessation, and moderation in alcohol consumption.